Track QIAGEN N.V. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

QIAGEN N.V. QGEN · Stock Open QIAGEN N.V. in new tab

49.89 USD
P/E
27.32
EPS
1.85
Yield
5.20%
Safety Score
60
P/B
3.00
ROE
10.81
Beta
0.56
Target Price
49.59 USD
QIAGEN N.V. logo

QIAGEN N.V.

🧾 Earnings Recap – Q3 2025

QIAGEN exceeded its financial targets for Q3 2025 with net sales up 6% to $533 million, sustaining growth momentum through strategic investments and operational efficiency.

  • Core sales grew 6% at constant exchange rates, outpacing the 4% target, with significant contributions from QIAstat diagnostics and QuantiFERON.
  • Adjusted EPS reached $0.61, surpassing guidance of at least $0.58, reflecting strong profitability despite external pressures.
  • The acquisition of Parse Biosciences enhances QIAGEN's position in the fast-evolving AI-driven single-cell market, while ongoing share repurchase plans aim for over $1 billion in shareholder returns by 2028.
  • The company reaffirmed its sales growth outlook of 4% to 5% at constant exchange rates for 2025, while raising adjusted EPS guidance to approximately $2.38, an increase of $0.10.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 3, 2027
P/E27.32
EPS1.85
Book Value16.83
Price to Book3.00
Debt/Equity47.44
% Insiders0.481%
Growth
Revenue Growth0.03%
Earnings Growth-0.19%
Estimates
Forward P/E18.97
Forward EPS2.66
Target Mean Price49.59
Dividend
Dividend Yield5.20%
Annual dividends2.64 USD
Ex-Div. DateJuly 7, 2026
Payout13.25%

DCF valuation

Model fair value for QIAGEN N.V. (QGEN)
Result
Sign in to run the valuation for QGEN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Hold · mean target 49.59 USD (low 40.00, high 53.00) · as of 10 Nov 2026
Low 40.00
Mean 49.59
High 53.00
Price 49.89
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

QIAGEN N.V. Logo QIAGEN N.V. Analysis (QGEN)

Netherlands Health Care Official Website Stock

Is QIAGEN N.V. a good investment? QIAGEN N.V. (QGEN) is currently trading at 49.89 USD. Market analysts have a consensus price target of 49.59 USD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 27.32. This valuation is generally in line with the broader market.

Earnings Schedule: QIAGEN N.V. is expected to release its next earnings report on Feb. 3, 2027. The market consensus estimate for Forward EPS is 2.66.

For income investors, QIAGEN N.V. pays a dividend yield of 5.20%. With a payout ratio of 13%, the dividend appears sustainable.

Investor FAQ

Does QIAGEN N.V. pay a dividend?

Yes, it pays an annual dividend of 2.64 USD (5.20% yield).

What asset class is QIAGEN N.V.?

QIAGEN N.V. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 3, 2027. The company currently has a trailing EPS of 1.85.

Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Exchange Ticker
GER (Germany) QIA.DE
NYQ (United States) QGEN
Trades
Dividend Yield
5.20%
Annual Dividends
2.64USD
Next Ex. Div Date
July 7, 2026
Payout Ratio
13.25%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
2.76 USD
July 14, 2027 (estimated) 0.3500
Jan. 8, 2027 (estimated) 2.4105
▸2026
2.76 USD
July 14, 2026 0.3500
Jan. 8, 2026 2.4105
▸2025
1.51 USD
July 10, 2025 0.2500
Jan. 29, 2025 1.2600
▸2024
1.28 USD
Jan. 31, 2024 1.2800
▸2017
1.08 USD
Jan. 25, 2017 1.0800
▸2002
0.03 USD
Dec. 27, 2002 0.0281
Upcoming Dividends
Name Payment Date Status Amount
QIAGEN N.V. Jul 14, 2026 0.35 USD
QIAGEN N.V. Jan 08, 2026 2.41053 USD
Stock Splits
Split Date Split Ratio to 1
July 16, 1999 2:1
July 14, 2000 4:1
Jan. 25, 2017 0.96
Jan. 30, 2024 0.97
Jan. 29, 2025 0.97
Jan. 8, 2026 0.95
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion